Sitemap > Breaking Research > Immunology & Inflammatory Diseases
Displaying 351 - 400 of 5698 results
- Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.
- An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion.
- Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis.
- Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide.
- Stable antibody expression at therapeutic levels using the 2A peptide.
- Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.
- Ibuprofen protects ischemia-induced neuronal injury via up-regulating interleukin-1 receptor antagonist expression.
- The development of monocyclic pyrazolone based cytokine synthesis inhibitors.
- 2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists.
- The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.
- Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
- C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation.
- Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
- In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
- The IkappaB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells.
- A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
- Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
- Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor.
- Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.
- An integral role for heme oxygenase-1 and carbon monoxide in maintaining peripheral tolerance by CD4+CD25+ regulatory T cells.
- Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation.
- Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.
- Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo.
- Blocking IL-15 prevents the induction of allergen-specific T cells and allergic inflammation in vivo.
- Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis.
- Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines.
- Role of interleukin-6 in mortality from and physiologic response to sepsis.
- Interleukin-15 enhances innate and adaptive immune responses to blood-stage malaria infection in mice.
- Interleukin-6 depletion selectively improves hepatic insulin action in obesity.
- Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands.
- Enhancement of fentanyl antinociception by subeffective doses of nitroparacetamol (NCX-701) in acute nociception and in carrageenan-induced monoarthritis.
- A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients: one year report.
- Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
- Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
- Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
- Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile.
- Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
- A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.
- Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness.
- TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage.
- mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer.
- Selective thromboxane A2 synthase inhibition by OKY-046 prevents cardiopulmonary dysfunction after ovine smoke inhalation injury.
- Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.
- Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia.
- Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.
- Immunomodulatory activities of small host defense peptides.
- Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.
- Central nervous system injury triggers hepatic CC and CXC chemokine expression that is associated with leukocyte mobilization and recruitment to both the central nervous system and the liver.
- Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists.
- Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 Next >